Patents by Inventor Marcus Michael FISCHER

Marcus Michael FISCHER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor
    Patent number: 12115163
    Abstract: Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.
    Type: Grant
    Filed: January 5, 2024
    Date of Patent: October 15, 2024
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Michael Patrick Dillon, Claire L. Neilan, Marcus Michael Fischer, Kimberline Yang Gerrick
  • COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR
    Publication number: 20240269143
    Abstract: Provided herein is a combination therapy and methods of using such combination therapy to treat diseases or disorders associated with MAT2A and/or Type I PRMT.
    Type: Application
    Filed: June 1, 2022
    Publication date: August 15, 2024
    Inventors: Michael Patrick DILLON, Marcus Michael FISCHER, Kimberline Yang GERRICK, Jenny Laraio, Helai Mohammad, Kimberly Smitheman
  • COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR
    Publication number: 20240173326
    Abstract: Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.
    Type: Application
    Filed: January 5, 2024
    Publication date: May 30, 2024
    Inventors: Michael Patrick DILLON, Claire L. NEILAN, Marcus Michael FISCHER, Kimberline Yang GERRICK
  • COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR
    Publication number: 20240108626
    Abstract: Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.
    Type: Application
    Filed: November 3, 2023
    Publication date: April 4, 2024
    Inventors: Michael Patrick DILLON, Claire L. NEILAN, Marcus Michael FISCHER, Kimberline Yang GERRICK